Mizutani, Hideaki
4 papers on CoChat
Most cited papers
- Verified
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 244
- Verified
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Carbone, D. P., Ciuleanu, T.-E., Schenker, M., Cobo, M., Bordenave, S., Juan-Vidal, O., Menezes, J., Reinmuth, N., Richardet, E., Cheng, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 65
- Verified
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial
Shiraishi, Y., Kishimoto, J., Sugawara, S., Mizutani, H., Daga, H., Azuma, K., Matsumoto, H., Hataji, O., Nishino, K., Mori, M., et al. (2024) · JAMA Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 54
- Verified
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
Carbone, D. P., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Felip, E., Cheng, Y., Juan-Vidal, O., et al. (2025) · ESMO Open
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 43
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free